Seminars in Clinical Research |
Type | Seminars in Clinical Research |
Title | Transforming Academic Drug Discovery in NYC: Applying Lessons Learned from the Discovery of Elbasvir for the Treatment of HCV |
Date | Wednesday, January 29, 2020 |
Time | 12:00 p.m. - 1:00 p.m. |
Location | 301 WRB |
Speaker(s) | Peter T. Meinke, Ph.D., Sanders Director, Tri-Institutional Therapeutics Discovery Institute |
Speaker Bio | Abstract: The discovery of elbasvir for the treatment hepatitis virus C (HCV) will be presented, starting from initial screening leads to final development compound. Lessons learned during these discovery efforts are being applied to transform academic drug discovery in NYC at the Tri-Institutional Therapeutics Discovery Institute (TDI, www.tritdi.org). TDI’s mission is to encourage our Tri-Institutional (Tri-I) community, made up of Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, to advance their groundbreaking biological discoveries to preclinical studies. TDI provides industrial-scale technical support for academic projects, making it possible to rapidly assess the utility of specific therapeutic targets in disease-relevant contexts. A TDI case study showing the development of novel inhibitors for a rare ocular disease, hypotony, will be presented. |
Open To | Tri-Institutional |
Host | Dr. Barry Coller |
Contact | Michelle Romanick |
Phone | 212-327-7316 |
Readings | http://clinfo.rockefeller.edu/seminar/2015-2018_Seminars_in_Clinical_Research/2019 Development of h-cGAS Inhibitors.pdf |
Readings | http://clinfo.rockefeller.edu/seminar/2015-2018_Seminars_in_Clinical_Research/2013 - Discovery of MK-1872.pdf |